Replies to post #2574 on RedHill Biopharma Ltd (RDHL)

[Spideyboy]

It is being given in severe cases of Covid-19.

That is the design of the study. But it could technically be used in less severe patients. If it is an orally bioavailable drug that stops viral replication in severe cases, and with the apparent strong safety indication, then I think it would be understandable for physicians to use it in less severe patients that might be likely to progress to severe. A key issue is the lack of space in Intensive Care Units, especially with the seasonal flu coming in which will take up more bed space. If a moderate progressing to severe patient could take the product, then this would be wonderful for the patient but also open up much needed space.

If referring to my statement:

"This would lend to the idea that all cells that get exposed to opaganib before infection could be saved, so treatment with opaganib would be better to be done as soon as possible and prior to other treatments."

Then what I mean by this is prior to other treatment types for severe patients. But again moderate patients may well benefit greatly.